Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

被引：0
|
作者：
Backes, Floor [1 ]
Wei, Lai [1 ]
Copeland, Larry [1 ]
Cohn, David [1 ]
Fowler, Jeffrey [1 ]
Bixel, Kristin [1 ]
Cosgrove, Casey [1 ]
Hays, John [1 ]
Myers, Molly [1 ]
Dodd, Kelly [1 ]
O'Malley, David [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
120
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 50 条
  • [41] Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study
    Xia, L.
    Zhou, Q.
    Zhang, Y.
    Gao, Y.
    Hu, W.
    Pan, M.
    Lou, G.
    Wang, L.
    Shi, H.
    Zhu, J.
    Sun, H.
    Wang, X.
    Wang, Q.
    Wu, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S630 - S630
  • [42] Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Dana M. Roque
    Eric R. Siegel
    Natalia Buza
    Stefania Bellone
    Dan-Arin Silasi
    Gloria S. Huang
    Vaagn Andikyan
    Mitchell Clark
    Masoud Azodi
    Peter E. Schwartz
    Gautam G. Rao
    Jocelyn C. Reader
    Pei Hui
    Joan R. Tymon-Rosario
    Justin Harold
    Dennis Mauricio
    Burak Zeybek
    Gulden Menderes
    Gary Altwerger
    Elena Ratner
    Alessandro D. Santin
    British Journal of Cancer, 2022, 126 : 1695 - 1703
  • [43] Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Roque, Dana M.
    Siegel, Eric R.
    Buza, Natalia
    Bellone, Stefania
    Silasi, Dan-Arin
    Huang, Gloria S.
    Andikyan, Vaagn
    Clark, Mitchell
    Azodi, Masoud
    Schwartz, Peter E.
    Rao, Gautam G.
    Reader, Jocelyn C.
    Hui, Pei
    Tymon-Rosario, Joan R.
    Harold, Justin
    Mauricio, Dennis
    Zeybek, Burak
    Menderes, Gulden
    Altwerger, Gary
    Ratner, Elena
    Santin, Alessandro D.
    BRITISH JOURNAL OF CANCER, 2022, 126 (12) : 1695 - 1703
  • [44] FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.
    Moore, Kathleen N.
    Vergote, Ignace
    Oaknin, Ana
    Colombo, Nicoletta
    Banerjee, Susana N.
    Oza, Amit M.
    Pautier, Patricia
    Kelly, Catherine Margaret
    Malek, Karim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study
    Coleman, R. L.
    Brady, W.
    McMeekin, D. S.
    Rose, P. G.
    Soper, J. T.
    Lentz, S. S.
    Hoffman, J. S.
    Shahin, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
    Dizon, Don S.
    Blessing, John A.
    Penson, Richard T.
    Drake, Richard D.
    Walker, Joan L.
    Johnston, Carolyn M.
    DiSilvestro, Paul A.
    Fader, Amanda Nickles
    GYNECOLOGIC ONCOLOGY, 2012, 125 (02) : 367 - 371
  • [47] A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Moore, K. N.
    Cadoo, K. A.
    Chambers, S.
    Ghamande, S.
    Konecny, G.
    Oza, A. M.
    Chen, L-M.
    Konstantinopoulos, P. A.
    Lea, J.
    Spitz, D.
    Uyar, D.
    Mugundu, G.
    Laing, N.
    Strickland, D. K.
    Jones, S.
    Burris, H.
    Spigel, D. R.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis
    Zhu, Youwen
    Lin, Yinxin
    Liu, Kun
    Zhu, Hong
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (06)
  • [49] Combined Weekly Topotecan and Biweekly Bevacizumab in Women With Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer Results of a Phase 2 Study
    McGonigle, Kathryn F.
    Muntz, Howard G.
    Vuky, Jacqueline
    Paley, Pamela J.
    Veljovich, Dan S.
    Greer, Benjamin E.
    Goff, Barbara A.
    Gray, Heidi J.
    Malpass, Thomas W.
    CANCER, 2011, 117 (16) : 3731 - 3740
  • [50] Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study
    Coleman, Robert
    Oaknin, Ana
    Pignata, Sandro
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason
    Marin, Margarita Romeo
    Harter, Philipp
    Murphy, Conleth
    Esteves, Brooke
    Method, Michael
    Lorusso, Domenica
    Matulonis, Ursula
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S3 - S3
12345